Substance / Medication

Trientine

Overview

Active Ingredient
trientine
RxNorm CUI
10798

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
New insights into the effects of dissolution profiles on the pharmacokinetics of trientine dihydrochloride.
Weiss Karl Heinz, Kruse Carlot, Abd-Elaziz Khalid et al. · Eur J Clin Pharmacol · 2025
PMID: 41428007RCT
Experience on switching trientine formulations in Wilson disease: Efficacy and safety after initiation of TETA 4HCl as substitute for TETA 2HCl.
Mohr Isabelle, Bourhis Hélène, Woimant France et al. · J Gastroenterol Hepatol · 2023
PMID: 36331262Observational
Multicentre, retrospective study to assess long-term outcomes of chelator based treatment with trientine in Wilson disease patients withdrawn from therapy with d -penicillamine.
Weiss Karl Heinz, Kruse Carlot, Manolaki Nina et al. · Eur J Gastroenterol Hepatol · 2022
PMID: 35482910Observational
Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine.
Brewer George J, Askari Fred, Dick Robert B et al. · Transl Res · 2009
PMID: 19595438Observational
Combination of copper-chelating agent, trientine, and methotrexate attenuates colorectal carcinoma development and angiogenesis in mice.
Yoshiji Hitoshi, Yoshii Junichi, Kuriyama Shigeki et al. · Oncol Rep · 2005
PMID: 15944792Observational
Hemorrhagic colitis induced by trientine in a 51-year-old patient with Wilson's disease waiting for liver transplantation: A case report.
Schult Andreas, Andersson Matts, Asin-Cayuela Jorge et al. · World J Hepatol · 2022
PMID: 36157863Case ReportFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Trientine (substance)
SNOMED CT
373456001
UMLS CUI
C0040976
RxNorm CUI
10798

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.